Physician profile
Jonathan C Campbell
NPI 1821065509
$1,783.92
in general payments reported to CMS, 2019-2025
25 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $174 · 2021: $496 · 2022: $210 · 2023: $160 · 2024: $142 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $696 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $695.77 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $411.42 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $311.43 | 2021-2023 | Qulipta, Vraylar |
| Indivior INC. | $95.20 | 2020-2025 | Sublocade |
| Amarin Pharma, INC. | $90.03 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $83.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $81.30 | 2019-2025 | Farxiga, Airsupra |
| Allergan, INC. | $73.87 | 2019-2020 | |
| Lilly USA, LLC | $72.20 | 2020-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $70.92 | 2024-2025 | |
| Abbott Laboratories | $56.96 | 2021-2023 | Freestyle Libre 2 |
| Pfizer INC. | $47.38 | 2021 | |
| Glaxosmithkline, LLC. | $46.20 | 2022-2025 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $41.80 | 2021-2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $41.02 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.82 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.79 | 2024 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $29.92 | 2021 | |
| Shire North American Group INC | $28.83 | 2019 | |
| Corcept Therapeutics | $27.48 | 2022-2023 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $25.31 | 2021 | |
| Almatica Pharma LLC | $25.11 | 2024 | Loreev Xr |
| Esperion Therapeutics, INC. | $14.89 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.59 | 2022 | |
| Daiichi Sankyo INC. | $14.39 | 2021 | |
| Boston Scientific Corporation | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.